French parliament OKs hep C drug rebate scheme
This article was originally published in Scrip
Executive Summary
The company rebate mechanism for the expensive new hepatitis C drugs including Gilead's Sovaldi will now be enshrined in French law, after the lower house of the parliament approved the social security financing bill (PLFSS) for 2015.